Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2012
09/27/2012US20120245518 Pharmaceutical composition for the treatment of bladder disorders
09/27/2012US20120245508 Synthesis of chlorins and phorbines with enhanced red spectral features
09/27/2012US20120245506 Combination of an oxidant, a photosensitizer and a wound healing agent for oral disinfection and treatment of oral disease
09/27/2012US20120245342 Methods for isolating crystalline form i of 5-azacytidine
09/27/2012US20120245231 Weight based dosing of an oral solution having diphenhydramine, or pharmaceutically acceptable salts thereof, as an active ingredient
09/27/2012US20120245230 Method and composition for preparing stable liquid formulations of paracetamol
09/27/2012US20120245229 Method for treating neuropathic pain
09/27/2012US20120245227 Pharmaceutical compositions having desirable bioavailability
09/27/2012US20120245226 Methods for treating attention-deficit/hyperactivity disorder
09/27/2012US20120245225 Novel benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof
09/27/2012US20120245224 Cannabinoids for use in the treatment of neuropathic pain
09/27/2012US20120245223 Use of gymnodimine, analogues and derivatives for the treatment and/or prevention of neurodegenerative diseases associated with tau and b-amyloid
09/27/2012US20120245222 Methods of using low-dose doxepin for the improvement of sleep
09/27/2012US20120245220 Nucleic acid molecules and methods for exchanging exon(s) by transsplicing
09/27/2012US20120245219 Minor groove binder (mgb)-oligonucleotide mirna antagonists
09/27/2012US20120245218 Surface modified nanoparticles, methods of their preparation, and uses thereof for gene and drug delivery
09/27/2012US20120245217 RNAi-MEDIATED INHIBITION OF HIF1A FOR TREATMENT OF OCULAR ANGIOGENESIS
09/27/2012US20120245216 Compositions and methods for treatment of neuropathic pain
09/27/2012US20120245215 Co-Crystals of Pyrrolidinones
09/27/2012US20120245214 Slow infusion of sulcardine and its salts
09/27/2012US20120245213 Human type i taste receptor subunit 3 modulators and methods of using same
09/27/2012US20120245212 Controlled release carvedilol formulation
09/27/2012US20120245211 Methods of Treating Cognitive Dysfunction by Modulating Brain Energy Metabolism
09/27/2012US20120245210 Novel Thiophene Inhibitors of S-Nitrosoglutathione Reductase
09/27/2012US20120245209 Heterocyclic sulfonamide derivatives
09/27/2012US20120245208 2-Oxo-1-Pyrrolidinyl Imidazothiadiazole Derivatives
09/27/2012US20120245207 Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
09/27/2012US20120245206 Multi-cyclic compounds and methods of use
09/27/2012US20120245205 Compositions and methods for inhibiting hair growth
09/27/2012US20120245203 Methods for treating heartburn and/or preventing gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
09/27/2012US20120245202 Methods and products for treating inflammation
09/27/2012US20120245201 Isopropylphenidate for Treatment of Attention-Deficit/Hyperactivity Disorder and Fatigue-Related Disorders and Conditions
09/27/2012US20120245200 Crystal form of quinoline compound and process for its production
09/27/2012US20120245199 [4 [4-(aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-(1h-pyrrolo-pyridin-yl)-methanones and synthesis thereof
09/27/2012US20120245198 Compounds and compositions for treatment of cancer
09/27/2012US20120245197 Pharmaceutical composition containing tosufloxacin or salt thereof
09/27/2012US20120245196 1-substituted 2-azabicyclo [3.1.1] heptyl derivatives useful as nicotinic acetylcholine receptor modulators for treating neurologic disorders
09/27/2012US20120245195 Novel monohydrate of azaadamantane derivatives
09/27/2012US20120245194 Small molecule inhibitors of the alpha4-paxillin interaction
09/27/2012US20120245193 PERIPHERIALLY ACTING μ OPIOID ANTAGONISTS
09/27/2012US20120245192 Pharmaceutical formulations containing rifaximin, processes for their obtainment and method of treating intestinal disease
09/27/2012US20120245191 New azaspirodecanone compounds
09/27/2012US20120245190 Autophagy inducing compound and the uses thereof
09/27/2012US20120245189 Crystalline cdc7 inhibitor salts
09/27/2012US20120245188 Methods of treating memory loss and enhancing memory performance
09/27/2012US20120245187 Heterobicyclic carboxamides as inhibitors for kinases
09/27/2012US20120245186 Combination cancer therapy with hsp90 inhibitory compounds
09/27/2012US20120245185 Aryl and heteroaryl sulfones as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
09/27/2012US20120245184 Small organic molecule regulators of cell proliferation
09/27/2012US20120245183 Macrocyclic lactone derivatives for the treatment of cancer
09/27/2012US20120245182 Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1--1-methyl-urea and salts thereof
09/27/2012US20120245181 Opioid receptor ligands and methods of using and making same
09/27/2012US20120245180 Combination
09/27/2012US20120245179 Method Of Therapeutic Administration of DHE To Enable Rapid Relief Of Migraine While Minimizing Side Effect Profile
09/27/2012US20120245178 Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor
09/27/2012US20120245177 Crystalline levofolinic acid and process for its preparation
09/27/2012US20120245176 Novel piperazine analogs with substituted heteroaryl groups as broad-spectrum influenza antivirals
09/27/2012US20120245175 Mk2 inhibitors
09/27/2012US20120245174 Compounds and methods for kinase modulation, and indications therefor
09/27/2012US20120245173 Inhibition of activated cdc42-associated kinase 1
09/27/2012US20120245172 Heterocyclic amine derivatives
09/27/2012US20120245171 Benzpyrazole derivatives as inhibitors of pi3 kinases
09/27/2012US20120245170 Pyrazolopyridine derivatives as anticancer agent
09/27/2012US20120245169 Certain chemical entities, compositions and methods
09/27/2012US20120245168 Composition, Synthesis, and Use of New Substituted Pyran and Pterin Compounds
09/27/2012US20120245166 Treatment of neurodegenerative diseases, causation of memory enhancement, and assay for screening compounds for such
09/27/2012US20120245165 Novel benzofuran type derivatives, a composition comprising the same for treating or preventing cognitive dysfunction and the use thereof
09/27/2012US20120245164 Diphenyl-pyrazolopyridine derivatives, preparation thereof, and use thereof as nuclear receptor not modulators
09/27/2012US20120245163 TRPV1 Antagonists
09/27/2012US20120245162 Oxadiazole inhibitors of leukotriene production
09/27/2012US20120245161 Indolyl-piperidinyl benzylamines as beta-tryptase inhibitors
09/27/2012US20120245160 Polymorphous forms iii and iv of n-benzoyl - staurosporine
09/27/2012US20120245158 Gamma secretase modulators
09/27/2012US20120245157 Oxazine derivatives
09/27/2012US20120245156 Oral lyophilized compositions
09/27/2012US20120245155 Fused heterocyclic compound having amino group
09/27/2012US20120245154 Substituted aminothiazine derivative
09/27/2012US20120245153 Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
09/27/2012US20120245152 3-(biaryoxy)propionic acid derivative
09/27/2012US20120245151 Bisfluoroalkyl-1,4-benzodiazepinone compounds
09/27/2012US20120245150 NOVEL (HETEROCYCLE/TETRAHYDROPYRIDINE)-(PIPERAZINYL)-1-ALCANONE AND (HETEROCYCLE/DIHYDROPYRROLIDINE)-(PIPERAZINYL)-1-ALCANONE DERIVATIVES, AND USE THEREOF AS p75 INHIBITORS
09/27/2012US20120245149 NOVEL (HETEROCYCLE/CONDENSED PIPERIDINE)-(PIPERAZINYL)-1-ALKANONE OR (HETEROCYCLE/CONDENSED PYRROLIDINE)-(PIPERAZINYL)-1-ALKANONE DERIVATIVES AND USE THEREOF AS p75 INHIBITORS
09/27/2012US20120245148 Tetrahydroquinoxaline uera derivatives, their preparation and their therapeutic application
09/27/2012US20120245147 Inhibitors of thapsigargin-induced cell death
09/27/2012US20120245146 Method of treatment of hormone depletion induced vasomotor
09/27/2012US20120245145 Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker
09/27/2012US20120245144 Benzoxazepin compounds selective for pi3k p110 delta and methods of use
09/27/2012US20120245143 3-0x0-2,3-dihydro-1h-isoindole-4-carboxamides with selective parp-1 inhibition
09/27/2012US20120245142 3-oxo-2,3-dihydro-1h-isoindole-4-carboxamides as parp inhibitors
09/27/2012US20120245141 Activators of human pyruvate kinase
09/27/2012US20120245140 N-containing heteroaryl derivatives as jak3 kinase inhibitors
09/27/2012US20120245139 Inhibitors of the hedgehog pathway
09/27/2012US20120245138 N-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl arylsulfonamides
09/27/2012US20120245137 Aryl sulphone derivatives as calcium channel blockers
09/27/2012US20120245136 Chroman-spirocyclic piperidine amides as modulators of ion channels
09/27/2012US20120245135 Gallium Complexes, Pharmaceutical Compositions And Methods Of Use
09/27/2012US20120245134 Androgen pharmaceutical composition and method for treating depression
09/27/2012US20120245133 Methods for the treatment of a traumatic central nervous system injury
09/27/2012US20120245132 Composition Comprising Benzoic Acid in Combination with Organic Acid Preservatives as Active Ingredients and the Use Thereof
09/27/2012US20120245131 6-substituted estradiol derivatives for use in remyelination of nerve axons
1 ... 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 ... 7860